Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

News Conference News AHA 2014

AVOIDing Oxygen in Suspected STEMI Tied to Smaller Infarcts, Less Recurrent MI

Yael L. Maxwell

November 18, 2014

News Conference News AHA 2014

Extending Clopidogrel Past 1 Year Improves Outcomes in DES, But Not BMS Patients

Yael L. Maxwell

November 16, 2014

News Conference News AHA 2012

Cell Therapy Trials Show Mixed Results at AHA 2012

November 05, 2012

News Conference News AHA 2012

EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES

Jason Kahn

November 04, 2012

News Conference News AHA 2012

FREEDOM: CABG Superior to PCI in Diabetic Patients with Multivessel Disease

November 04, 2012

News Conference News

No LateTIME Benefit for Cell Therapy After Primary PCI

November 14, 2011

News Conference News

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

November 13, 2011

Advertisement

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

AVOIDing Oxygen in Suspected STEMI Tied to Smaller Infarcts, Less Recurrent MI

Extending Clopidogrel Past 1 Year Improves Outcomes in DES, But Not BMS Patients

Cell Therapy Trials Show Mixed Results at AHA 2012

EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES

FREEDOM: CABG Superior to PCI in Diabetic Patients with Multivessel Disease

No LateTIME Benefit for Cell Therapy After Primary PCI

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content